Shareholders Approve MDS Analytical Technologies Sale
Earlier this month, Danaher reiterated in its quarterly conference call that it is confident that the acquisition will close in the fourth quarter. The acquisition will combine MDS’s and Life Technologies’ 50-50 share of their MS joint venture and also includes the Molecular Devices and MDS’ manufacturing partnership with PerkinElmer. Life Technologies’s share of the MS joint venture reported third-quarter sales of $111 million, a 3% increase on an organic basis.
Toronto, Canada 10/20/09—MDS shareholders have approved the sale of the company’s Analytical Technologies business to Danaher for $650 million in cash (see IBO 9/15/09). More than 99% of the common shares voted approved the sale in a special meeting held on October 20. The sale remains subject to regulatory approval.
